key: cord-0315572-1thnwvwy authors: GOUNANT, V.; FERRE, V. M.; SOUSSI, G.; charpentier, C.; FLAMENT, H.; FIDOUH, N.; COLLIN, G.; NAMOUR, C.; ASSOUN, S.; BIZOT, A.; BROUK, Z.; VICAUT, E.; TEXEIRA, L.; DESCAMPS, D.; ZALCMAN, G. title: Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses date: 2021-08-13 journal: nan DOI: 10.1101/2021.08.12.21261806 sha: 4f2f298ac111f6c38ec4b1dd6c880c2992300f7a doc_id: 315572 cord_uid: 1thnwvwy Hypothesis Coronavirus disease 2019 (COVID-19) resulted in a 30% mortality rate in thoracic cancer patients. Given that cancer patients were excluded from serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine registration trials, it is still unknown whether they would develop a protective anti-spike antibody response following vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to SARS-CoV2 vaccine in thoracic cancer patients. Methods SARS-CoV2-spike antibodies were measured using Abbot ARCHITECT SARS-CoV-2 IgG immunoassay, prior to first injection of BNT162b2 mRNA vaccine, as well as at Week 4, and two-to-sixteen weeks after second vaccine dose. The factors associated with antibody response were analyzed. Results Overall, 306 patients, with a median age of 67.0 years (IQR=58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After 4.7-month median follow-up, seven patients (2.3%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of 269 serological results available beyond Day 14 post-second vaccine dose, 17 (6.3%) were still negative (<50 AU/mL) (arbitrary units/mL), while 34 (11%) were <300 AU/mL (12.5th percentile). In multivariate analysis, only age and chronic corticosteroid treatment were significantly associated with a lack of immunization. Thirty patients received a third vaccine dose, with only three patients showing persistent negative serology thereafter, whereas the others demonstrated clear seroconversion. Conclusion SARS-CoV2 vaccines were shown to be efficient in thoracic cancer patients, most of them being immunized after two doses. A third shot given to 11% of patients with persistent low antibody titers resulted in a 88% immunization rate. Coronavirus disease 2019 is associated with a dramatic 30% mortality rate in thoracic cancer patients 1,2, 3 . The Chinese series reported mortality rates of 29-39%, 4-6 compared with 0.7-8.0% case fatality rates in their general population 7-11 . Lung cancer patients should therefore be given priority for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Nonetheless, active cancer condition and immunosuppressive therapy constituted non-inclusion criteria for SARS-CoV-2 vaccine registration trials, and scarcely anything is known about the vaccine effectiveness in cancer populations. Moreover, the antibody response after influenza vaccination was previously shown to be lower in cancer patients versus healthy controls, especially concerning people aged >65 years 12 . Notably, two doses of influenza vaccine were required in cancer patients to attain the same serum protection rate than in healthy controls, with on-going chemotherapy or corticosteroids resulting in lower protection 13 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Ad26.COV2.S 19 or two doses of Astra-Zeneca ChAdOx1nCov-19 vaccines 20, 21 ), slightly lower rates were reported. Similar protection rates against severe COVID19 were confirmed in real-life by population-based Israeli and Scottish studies for Pfizer BNT162b2 or 23 . Yet, these data cannot be extrapolated to cancer patients undergoing anti-cancer treatment. Duration of anti-SARS-CoV-2spike (anti-S) detection was at least 8 months in healthy volunteers 24 . It is unclear whether such duration is applicable to cancer patients receiving immunosuppressing drugs. Early January 2021, vaccination was made available in France. To increase first vaccine dose availability, French Health authorities recommended a 28-day interval for both mRNA vaccines, with a 42-day interval for healthy people, this delayed second dosing being debatable 25, 26 . Due to uncertainties concerning vaccination of cancer patients, the observational COVIDVAC-OH study (clinical.trials.gov NCT04776005) Hospitals. This study sought to investigate SARS-CoV-2 vaccination's (mainly mRNA-based vaccines) effectiveness in over 1100 consecutive patients with solid cancers or hematological malignancies, at North-Paris University Cancer center. This report concerns 306 thoracic cancer patients. We conducted a prospective study involving thoracic cancer patients followed-up in Bichat Hospital, from January 26 to July 28, 2021. Patients diagnosed with thoracic cancer and deemed eligible (no known COVID-19 infection within 3 months; lack of known allergy to previous vaccines) were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 identified from medical records. They were contacted and offered to be vaccinated. If they accepted and in the absence of contra-indications, they were attended vaccination sessions in the outpatient clinic, according to priority sequencing, as follows: first elderly patients aged >75 years and those receiving chemotherapy; patients receiving immune checkpoint inhibitors (ICI); patients with pneumonectomy or chronic radiation pneumonitis; patients on oral tyrosine kinase targeted therapy (TKIs); patients without systemic therapy. They were given a written information leaflet on COVID19 mRNA BNT162b2 vaccine, and on serological and hematological blood tests to be performed at first dose (Day 0), at second dose (Day 28), and at least 2 weeks post-booster dose (Day 42). All patients could oppose blood samplings and still undergo vaccine injections. Recommendations to keep facial masks and social distancing were given. All patients were registered into National Health Insurance computed COVID-19 vaccine database, with national identification number, complete identity, main underlying conditions, and vaccine batch number. Following blood sampling and vaccine injection, patients were followed-up for 15 minutes under medical surveillance 27 . This study was approved by the Comité d'Evaluation de l'Ethique des projets de Recherche Biomedicale (CEERB, IRB00006477) of University Hospitals Paris-North Val-de-Seine, Paris 7 University, Assistance Publique-Hôpitaux de Paris (AP-HP) upon the approval number N°CER-2021-72. In the case of COVID-19-suggestive symptoms, patients were instructed to promptly inform the medical team and perform nasopharyngeal SARS-CoV-2 RT-PCR swab testing. At second vaccination visit, they were questioned about undesirable events post-first vaccination and symptoms evoking COVID-19. Some patients (n=16) were vaccinated by their general practitioner or in a governmentcertified vaccination center. No blood sampling was available for these patients at . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Days 0 and 28. If they agreed, they underwent blood sampling in the post-booster period and were included in our study. To set up the technical conditions for SARS-CoV-2 anti-nucleocapsid (N) index and anti-Spike antibody determination, 18 control subjects from Hôpital Bichat staff, without previous COVID-19 symptoms or PCR-proved SARS-CoV-2 infection, provided their written consent for blood sampling. This occurred on Day 28 post-first vaccine, while 13 subjects underwent additional blood sampling at least 2 weeks post-second vaccine. The primary endpoint was to assess humoral immunity against SARS-CoV-2-spike in thoracic cancer patients following COVID-19 mRNA BNT162b2 vaccine injection and booster dose. Some patients vaccinated outside our center received Moderna mRNA-1273 (n=1) or Astra-Zeneca ChAdOx1 nCov-19 (n=3) vaccines, being included herein. Secondary endpoints were vaccination safety, clinical efficacy based on RT-PCRdocumented COVID-19 infection during the study, and hospitalization or death from COVID-19. Phone safety consultations were scheduled every 3 weeks. Cell immunity to SARS-CoV-2-spike protein was evaluated using T-cell enzyme linked immunospot (ELISPOT), with lymphocyte subset counts, scheduled at Day 28 and from Day 42 post-first injection in 122 arbitrarily-designated patients. SARS-CoV-2 anti-N and anti-S antibody titers were determined using Abbott Architect SARS-CoV-2 IgG and IgG Quant II (Abbott, Maidenhead, UK) and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 expressed as index (cut-off: 0.49) and arbitrary units (cut-off: 50 AU/mL), respectively. Pseudo-neutralization assay was performed using iFlash-2019-nCoV Nab assay (YHLO, Shenzhen, China), which assesses antibody neutralizing capacity by competition with angiotensin-converting enzyme 2 (ACE2)-receptor for binding to anti-spike RBD (cut-off: 10AU/mL). This assay correlated with SARS-CoV-2 in vitro cell micro-neutralization (paper submitted for publication). All samples were de-identified and assigned an ID number, with the sampling date. Sample processing and data analyses were performed, with all study personal blinded to information concerning patients and samples. De-identified data were exported from Microsoft Excel Version 2013 for Windows (Microsoft Corporation, 2013) to IBM® SPSS® Statistics for Windows, Version 25.0 (IBM Corp., Armonk, N.Y., USA) for statistical analysis. Between-group comparisons were performed using Pearson's chi-squared or Fisher's exact tests for discrete variables, and Student's-T or Mann-Whitney U tests for continuous variables. Odds ratios (OR) and respective 95% confidence intervals (95%CI) were calculated using binary logistic regression. Hypothesis testing was two-tailed, with p values<0.05 considered statistically significant. All assumptions required for logistic regression modeling were verified. Multivariable analysis was conducted using binary logistic regression using the Enter method, including variables exhibiting a significance threshold p<0.20 yielded by the univariable analysis.. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 The academic authors retained editorial control. The Assistance Publique-Hôpitaux de Paris funded the study, without participating to study design, data collection, data analysis, data interpretation, or report writing. From January 20 to June 1, 2021, overall 325 thoracic cancer patients followed-up in thoracic oncology/surgery departments were proposed anti-SARS-CoV-2 vaccination with Pfizer BNT162b2 mRNA vaccine. Initially, only 36 (11%) declined the proposal. Of these, 17 eventually accepted to be vaccinated; nine of whom were vaccinated outside of our center but participated to serological testing. Overall, 306 patients received their 28-day-spaced doses or underwent blood samplings between January 26 and May 17, 2021. Patient disposition is illustrated in suppl. Figure 1 . Clinical follow-up was extended until July 28, 2021. Patient clinical and demographic characteristics are provided in Table 1 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261806 doi: medRxiv preprint In patients without symptomatic or asymptomatic COVID-19 (thus excluding twentytwo patients, 17 with prior COVID-19 history, 3 with PCR-proved COVID-19 post-1st dose, and 2 with anti-N IgG detected at D0) history, a striking increase in antibody titers occurred between Day 0 (137 patients with available serology) and Day 28 (248 patients with available serology) post-first vaccine ( Figure 1A) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure 1B) . No significant differences in serum anti-spike antibody titers were seen between chemotherapy-and immunotherapy-treated patients (p=0.11). The second booster dose was not administered to 24 patients due to cancer-related general condition alteration (n=2), mild symptomatic PCR-proven COVID-19 infection post-first vaccine (n=3), history of symptomatic COVID-19 before vaccination supported by anti-N IgG detection (n=17), and totally asymptomatic COVID-19as reflected again by anti-N IgG detection (n=2). Serological data were available for 269 (88%) patients at Day 42, two-to-nine weeks . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. Among patients free of prior SARS-CoV-2 infection or with anti-N negative IgG at D0 and D28 (n=265), 248 samples were available at D42 (>14 days post-second dose) with median serum anti-S IgG titer at 4725 AU/mL IQR(1066 -13698), 300 AU/mL corresponding to 12.5 th percentile. Two-to-nine weeks post-second vaccine, an overall increase in serum anti-S IgG titers was noted ( Figure 1C ) with a mean 1.4-to-2-fold increase in the log 10 anti-spike IgG concentrations. However, 17 patients (6.3%) still exhibited negative serological testing, while 34 (11%) displayed IgG concentrations ≤ 300 AU/mL, with 65 patients (24.1%) exhibiting antibody titers below the first quartile value of 1066 UA/mL. The median serum anti-S IgG concentration in 13 healthy controls, within a median 57-day interval post-second vaccine, was 10594 AU/mL IQR(8350-14836). The titer distribution significantly differed from that observed in patients treated using chemotherapy (p=0.0003, Mann-Whitney), immunotherapy (p=0.013, Mann-Whitney), oral targeted therapy or bevacizumab (p=0.02, Mann-Whitney), or those without systemic therapy